Pyrimidine Compounds Targeting EGFR and ERBB2 Exon 20 Insertions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for EGFR and HER2 exon 20 insertion mutations, which are prevalent in non-small cell lung cancer, leading to low response rates and limited clinical efficacy for patients.
Innovation Solution
Development of specific pyrimidine compounds and their pharmaceutically acceptable salts that target EGFR and ERBB2 exon 20 insertion mutations, offering improved therapeutic options for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If marketed EGFR TKIs (Erlotinib/Gefitinib/Afatinib) are used for treatment, then general EGFR inhibition is achieved, but efficacy against EGFR and HER2 exon 20 insertion mutations is insufficient with low response rates
Solution Approach 1:
The patent develops compounds with specific structural features (pyrimidine core with particular substituent patterns) that are optimized to recognize and bind to the unique structural characteristics of exon 20 insertion mutations. This local optimization of molecular properties enables selective high-affinity binding to mutant EGFR/HER2 while maintaining broader activity across mutation types, resolving the contradiction between specialized efficacy and general adaptability
2Adaptability or versatility
If second-generation EGFR inhibitors (afatinib and dacomitinib) are used, then broader EGFR coverage is achieved, but effectiveness against exon 20 insertion mutations remains limited
Solution Approach 1:
The patent employs systematic modification of key molecular parameters including substituent types (R1-R6 groups), ring structures, and molecular weight to optimize the balance between broad mutation coverage and exon 20 specificity. By tuning these chemical parameters, the compounds achieve enhanced binding affinity for exon 20 mutations while maintaining activity against other EGFR/HER2 variants, resolving the trade-off between versatility and reliability
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.